Evidence map›Paper›PMID 28830942›Full record

ArticlemBio2017

Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE.

Travis B Nielsen, Paul Pantapalangkoor, Jun Yan, Brian M Luna, Ken Dekitani, Kevin Bruhn, Brandon Tan, Justin Junus, Robert A Bonomo, Ann Marie Schmidt and 5 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Observational
  5. Observational
  6. Review
  7. Review
  8. Article
  9. Article
  10. Enhanced Vulnerability of Diabetic Mice to HypervirulentPathogens (Basel, Switzerland) · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Travis B NielsenDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA travis.nielsen@gmail.com.
Paul PantapalangkoorDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Jun YanDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Brian M LunaDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Ken DekitaniDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Kevin BruhnDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Brandon TanDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Justin JunusDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
Robert A BonomoDepartments of Medicine, Pharmacology and Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Ann Marie SchmidtDepartments of Medicine, Biochemistry and Molecular Pharmacology and Pathology, New York University, New York, New York, USA.
Michael EversonEisai, Inc., Tokyo, Japan.
Frederick DuncansonEisai, Inc., Tokyo, Japan.
Terence M DohertyLos Angeles Biomedical Research Institute, Torrance, California, USA.
Lin LinLos Angeles Biomedical Research Institute, Torrance, California, USA.
Brad SpellbergDepartment of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine at the University of Southern California (USC), Los Angeles, California, USA.
University of Southern California · USEisai (Japan) · JPThe Lundquist Institute · USLouis Stokes Cleveland VA Medical Center · USNew York University · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Translational Research CoreP30DK020541 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY E. PESSIN · 2015 to 2026
$27.7M
MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
Humanized Monoclonal Antibody to Treat Acinetobacter InfectionsR42AI106375 · NIAID · BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC · PI ISLAM, KHALID · 2016 to 2018
$3.1M
Transferrin Combination Therapy to Address Antimicrobial ResistanceR01AI117211 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2016 to 2019
$2.7M
Activated Targeted Killer (ATAK) Cells for Invasive Fungal InfectionsR01AI081719 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SPELLBERG, BRAD J · 2009 to 2013
$1.7M
Diabetes and Inflammation During InfectionR21AI127954 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SPELLBERG, BRAD J · 2017 to 2018
$454k
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–
BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI081719NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI117211NIAID NIH HHS R01 AI130060NIAID NIH HHS R21 AI127954NIAID NIH HHS R42 AI106375NIAID NIH HHS UM1 AI104681NIDDK NIH HHS P30 DK020541
6 · The paper itself

Abstract

For more than a century, diabetic patients have been considered immunosuppressed due to defects in phagocytosis and microbial killing. We confirmed that diabetic mice were hypersusceptible to bacteremia caused by Gram-negative bacteria (GNB), dying at inocula nonlethal to nondiabetic mice. Contrary to the pervasive paradigm that diabetes impedes phagocytic function, the bacterial burden was no greater in diabetic mice despite excess mortality. However, diabetic mice did exhibit dramatically increased levels of proinflammatory cytokines in response to GNB infections, and immunosuppressing these cytokines with dexamethasone restored their resistance to infection, both of which are consistent with excess inflammation. Furthermore, disruption of the receptor for advanced glycation end products (RAGE), which is stimulated by heightened levels of AGEs in diabetic hosts, protected diabetic but not nondiabetic mice from GNB infection. Thus, rather than immunosuppression, diabetes drives lethal hyperinflammation in response to GNB by signaling through RAGE. As such, interventions to improve the outcomes from GNB infections should seek to suppress the immune response in diabetic hosts.

Indexed as

AnimalsBacterial LoadCytokinesDiabetes Mellitus, ExperimentalDisease ProgressionGram-Negative Bacterial InfectionsInflammationMiceMyeloid Differentiation Factor 88PhagocytosisReceptor for Advanced Glycation End ProductsSignal TransductionToll-Like Receptor 4Ager protein, mouseCytokinesMyd88 protein, mouseMyeloid Differentiation Factor 88Receptor for Advanced Glycation End ProductsTlr4 protein, mouseToll-Like Receptor 4diabetes mellitusGram-negative bacteriainfectioninflammationRAGETLR4

Identifiers

PMID28830942
PMCPMC5565964
OpenAlexW2748227714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.